[A new therapy with bortezomib, an oncologic medicinal product of the year 2004]

Area of Science:

• Cellular Biology
• Biochemistry
• Molecular Biology

Context:

• Proteasome-mediated proteolysis is a critical cellular process for regulating protein levels.
• This system targets proteins for degradation via poly-ubiquitin tagging and recognition by the 19S proteasome subunit.
• Key cellular targets include tumor suppressors (p53), NF-kappaB, and cyclin-dependent kinase inhibitors (p21, p27).

Purpose:

• To highlight the significance of proteasome-mediated protein degradation in cellular regulation.
• To underscore the proteasome's role as a therapeutic target in cancer treatment.
• To provide context on the development and approval of proteasome inhibitors like Velcade.

Summary:

• Proteasome-mediated proteolysis involves tagging proteins with poly-ubiquitin chains for degradation.
• This pathway regulates crucial proteins, including those involved in cancer progression.
• The proteasome inhibitor Velcade (PS-341) is approved for multiple myeloma treatment.

Impact:

• The proteasome pathway's regulation of cellular targets makes it a viable strategy for cancer therapy.
• The development of selective proteasome inhibitors has led to new treatment options for hematological malignancies.
• The Nobel Prize in Chemistry 2004 recognized the fundamental discovery of ubiquitin-mediated protein degradation.